Bill > HR8013

This bill, the End Taxpayer Funding of Gender Experimentation Act of 2020, would prohibit the use of federal funds for gender reassignment medical interventions, including surgeries, medications, and treatments. The bill also prohibits federal health benefits plans from covering such interventions, with exceptions for individuals born with medically verifiable disorders of sex development. Additionally, the bill clarifies that the prohibition applies to premium credits and cost-sharing reductions under the Affordable Care Act (ACA), and excludes plans that cover gender reassignment interventions from the small employer health insurance expense credit.